Provectus assigns exclusive ophthalmic license to majority-owned subsidiary VisiRose

PROVECTUS BIOPHARMACEUTICALS, INC.

Assigns exclusive license with University of Miami for photodynamic antimicrobial therapy in ophthalmology to VisiRose, effective Dec 9, 2024.
VisiRose is a majority-owned subsidiary focused on developing rose bengal sodium for ophthalmology diseases and disorders.
University of Miami approved assignment and novation, releasing Provectus from future obligations under the license.
Provectus grants VisiRose a non-exclusive, worldwide, royalty-free license to Licensee Background IP as needed.
Agreement reflects Provectus's strategy to separate ophthalmic assets into a dedicated subsidiary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.